Puretech Health
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2001-01-01
- Employees
- 90
- Market Cap
- $598.2M
- Website
- https://puretechhealth.com
- Introduction
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. It operates through the following segments: Internal, Controlled Founded Entities, Non...
Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- PureTech
- Target Recruit Count
- 30
- Registration Number
- NCT06717100
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
- Conditions
- Interventions
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- PureTech
- Target Recruit Count
- 90
- Registration Number
- NCT05829226
- Locations
- 🇺🇸
Mass. General Hospital-Harvard, Boston, Massachusetts, United States
🇺🇸Virginia Commonwealth University Medical Center, Richmond, Virginia, United States
🇺🇸Baptist Health South Florida-Miami Cancer Institute, Miami, Florida, United States
LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Conditions
- Interventions
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- PureTech
- Target Recruit Count
- 240
- Registration Number
- NCT05321420
- Locations
- 🇺🇸
Indiana University School of Medicine, Indianapolis, Indiana, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸Science 37, Los Angeles, California, United States
LYT-300 in Healthy Volunteers
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- PureTech
- Target Recruit Count
- 186
- Registration Number
- NCT05129865
- Locations
- 🇦🇺
CMAX, Adelaide, South Australia, Australia
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- PureTech
- Target Recruit Count
- 80
- Registration Number
- NCT04666688
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
🇺🇸University of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States
LYT-100 in Post-acute COVID-19 Respiratory Disease
- Conditions
- Interventions
- First Posted Date
- 2020-12-03
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- PureTech
- Target Recruit Count
- 185
- Registration Number
- NCT04652518
- Locations
- 🇺🇸
University of Southern California - Keck School of Medicine, Los Angeles, California, United States
🇺🇸Center for Advanced Research and Education, Gainesville, Georgia, United States
🇺🇸GenHarp Clinical Solutions, Evergreen Park, Illinois, United States
LYT-100 in Patients With BCRL
- Conditions
- Interventions
- First Posted Date
- 2020-01-28
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- PureTech
- Target Recruit Count
- 50
- Registration Number
- NCT04243837
- Locations
- 🇺🇸
MACRO Trials, Los Angeles, California, United States
🇺🇸Accel Research Network, Atlanta, Georgia, United States
🇦🇺Macquarie University Health Sciences Centre, Sydney, Australia